JP2006521399A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006521399A5 JP2006521399A5 JP2006509357A JP2006509357A JP2006521399A5 JP 2006521399 A5 JP2006521399 A5 JP 2006521399A5 JP 2006509357 A JP2006509357 A JP 2006509357A JP 2006509357 A JP2006509357 A JP 2006509357A JP 2006521399 A5 JP2006521399 A5 JP 2006521399A5
- Authority
- JP
- Japan
- Prior art keywords
- neuropathic pain
- compound
- receptor subtype
- selectively activates
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 208000004296 neuralgia Diseases 0.000 claims 13
- 208000021722 neuropathic pain Diseases 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- 208000004454 Hyperalgesia Diseases 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 208000018380 Chemical injury Diseases 0.000 claims 2
- 208000035154 Hyperesthesia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 206010053552 allodynia Diseases 0.000 claims 2
- 238000002266 amputation Methods 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45904503P | 2003-03-28 | 2003-03-28 | |
| PCT/US2004/009339 WO2004087158A2 (en) | 2003-03-28 | 2004-03-26 | Muscarinic m1 receptor agonists for pain management |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006521399A JP2006521399A (ja) | 2006-09-21 |
| JP2006521399A5 true JP2006521399A5 (enExample) | 2007-05-10 |
Family
ID=33131858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006509357A Withdrawn JP2006521399A (ja) | 2003-03-28 | 2004-03-26 | 疼痛管理用ムスカリンｍ１受容体アゴニスト |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20050130961A1 (enExample) |
| EP (1) | EP1613321A2 (enExample) |
| JP (1) | JP2006521399A (enExample) |
| KR (1) | KR20050112116A (enExample) |
| CN (1) | CN1777425A (enExample) |
| AU (1) | AU2004226430A1 (enExample) |
| BR (1) | BRPI0409523A (enExample) |
| CA (1) | CA2520125A1 (enExample) |
| MX (1) | MXPA05010171A (enExample) |
| NZ (1) | NZ542690A (enExample) |
| RU (1) | RU2358735C2 (enExample) |
| WO (1) | WO2004087158A2 (enExample) |
| ZA (1) | ZA200508733B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002359875B2 (en) * | 2001-12-28 | 2009-01-08 | Acadia Pharmaceuticals Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| US7550459B2 (en) | 2001-12-28 | 2009-06-23 | Acadia Pharmaceuticals, Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
| KR20070036149A (ko) * | 2004-07-16 | 2007-04-02 | 얀센 파마슈티카 엔.브이. | 이량체 피페리딘 유도체 |
| EP2275095A3 (en) * | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
| JP2009536669A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス，インコーポレイティド | アンジオテンシン調節による神経新生 |
| AU2007292848A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| JP2010504359A (ja) | 2006-09-20 | 2010-02-12 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 局部麻酔および／または疼痛緩和のための、揮発性麻酔剤を送達するための方法 |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| SI2091948T1 (sl) | 2006-11-30 | 2012-07-31 | Probiodrug Ag | Novi inhibitorji glutaminil ciklaze |
| CN101668525A (zh) | 2007-03-01 | 2010-03-10 | 前体生物药物股份公司 | 谷氨酰胺酰环化酶抑制剂的新用途 |
| EP2142514B1 (en) | 2007-04-18 | 2014-12-24 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| AU2009206390B2 (en) | 2008-01-22 | 2014-10-30 | The Board Of Regents Of The University Of Texas System | Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| KR101790806B1 (ko) | 2010-03-10 | 2017-11-20 | 프로비오드룩 아게 | 글루타미닐 사이클라제(ｑｃ, ｅｃ 2.3.2.5)의 헤테로사이클릭 억제제 |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| EP2976079A1 (en) * | 2013-03-15 | 2016-01-27 | Acadia Pharmaceuticals Inc. | Muscarinic agonists |
| WO2015163485A1 (en) | 2014-04-23 | 2015-10-29 | Takeda Pharmaceutical Company Limited | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease |
| KR20180019234A (ko) | 2015-06-26 | 2018-02-23 | 다케다 야쿠힌 고교 가부시키가이샤 | 콜린성 무스카린 m1 수용체의 조절제로서의 2,3-디히드로-4h-1,3-벤족사진-4-온 유도체 |
| US10548899B2 (en) | 2015-10-20 | 2020-02-04 | Takeda Pharmaceutical Company Limited | Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity |
| DK3461819T3 (da) | 2017-09-29 | 2020-08-10 | Probiodrug Ag | Inhibitorer af glutaminylcyklase |
| US20220144817A1 (en) * | 2019-02-22 | 2022-05-12 | Karuna Therapeutics, Inc. | Compounds and methods of deuterated xanomeline for treating neurological disorders |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8717446D0 (en) * | 1987-07-23 | 1987-08-26 | Merck Sharp & Dohme | Chemical compounds |
| US5155166A (en) * | 1990-06-18 | 1992-10-13 | Eastman Kodak Company | Use of 1-(1-pyrrolidinylcarbonyl)pyridinium salts to attach compounds to carboxylated particles and a kit containing same |
| FR2663929A1 (fr) * | 1990-06-29 | 1992-01-03 | Adir | Nouveaux derives d'oxazolo pyridines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| IL110298A (en) * | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| GB2292685A (en) * | 1994-07-27 | 1996-03-06 | Sankyo Co | Allosteric effectors at muscarinic receptors |
| US6271196B1 (en) * | 1996-03-05 | 2001-08-07 | Regents Of The University Of Ca | Methods of alleviating neuropathic pain using prosaposin-derived peptides |
| FR2747041B1 (fr) * | 1996-04-05 | 1998-05-22 | Cird Galderma | Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies |
| US6528529B1 (en) * | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| AU1596099A (en) * | 1998-11-23 | 2000-06-13 | Eisai Co. Ltd. | Aryl and heteroaryl compounds useful as fibroblast growth factor antagonists |
| AR028385A1 (es) * | 2000-04-28 | 2003-05-07 | Acadia Pharm Inc | Agonistas muscarinicos |
| KR20040047877A (ko) * | 2001-10-02 | 2004-06-05 | 아카디아 파마슈티칼스 인코포레이티드 | 무스카린 제제로서 벤즈이미다졸리디논 유도체 |
| AU2002359875B2 (en) * | 2001-12-28 | 2009-01-08 | Acadia Pharmaceuticals Inc. | Tetrahydroquinoline analogues as muscarinic agonists |
-
2004
- 2004-03-26 BR BRPI0409523-5A patent/BRPI0409523A/pt not_active IP Right Cessation
- 2004-03-26 WO PCT/US2004/009339 patent/WO2004087158A2/en not_active Ceased
- 2004-03-26 CN CNA2004800104664A patent/CN1777425A/zh active Pending
- 2004-03-26 EP EP04758412A patent/EP1613321A2/en not_active Withdrawn
- 2004-03-26 RU RU2005133197/14A patent/RU2358735C2/ru active
- 2004-03-26 KR KR1020057018253A patent/KR20050112116A/ko not_active Ceased
- 2004-03-26 CA CA002520125A patent/CA2520125A1/en not_active Abandoned
- 2004-03-26 MX MXPA05010171A patent/MXPA05010171A/es unknown
- 2004-03-26 AU AU2004226430A patent/AU2004226430A1/en not_active Abandoned
- 2004-03-26 NZ NZ542690A patent/NZ542690A/en unknown
- 2004-03-26 US US10/809,975 patent/US20050130961A1/en not_active Abandoned
- 2004-03-26 JP JP2006509357A patent/JP2006521399A/ja not_active Withdrawn
-
2005
- 2005-10-27 ZA ZA200508733A patent/ZA200508733B/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006521399A5 (enExample) | ||
| JP2007145875A5 (enExample) | ||
| JP2011528713A5 (enExample) | ||
| JP2004534850A5 (enExample) | ||
| JP2021063088A5 (enExample) | ||
| JP2009511595A5 (enExample) | ||
| RU2005133197A (ru) | Агонисты м1 мускариновых рецепторов для противоболевой терапии | |
| JP2009514835A5 (enExample) | ||
| JP2010522242A5 (enExample) | ||
| JP2008524331A5 (enExample) | ||
| JP2009514836A5 (enExample) | ||
| JP2007537301A5 (enExample) | ||
| JP2012509348A5 (enExample) | ||
| JP2009514837A5 (enExample) | ||
| JP2003503454A5 (enExample) | ||
| JP2010515715A5 (enExample) | ||
| JP2009501178A5 (enExample) | ||
| CL2011000571A1 (es) | Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma. | |
| JP2006523216A5 (enExample) | ||
| NZ710575A (en) | Pharmaceutical compositions for the treatment of diabetes mellitus | |
| BR0211414A (pt) | Composto, uso do mesmo, composição farmacêutica, e, métodos para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e de diabetes tipo i, diabetes tipo ii, tolerância à glicose, resistência à insulina ou obesidade prejudicadas | |
| JP2011505356A5 (enExample) | ||
| RU2005126412A (ru) | Сор1 для лечения воспалительных заболеваний кишечника | |
| JP2008513510A5 (enExample) | ||
| RU2020109881A (ru) | Агонисты рецепторов glp-1/глюкагона в лечении жировой болезни печени и стеатогепатита |